Search our Database of Scientific Publications and Authors

I’m looking for a

    4254 results match your criteria Urticaria Chronic

    1 OF 86

    [Helicobacter pylori infection and extragastroduodenal diseases].
    Ter Arkh 2015 ;87(8):103-110
    A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia.
    At present, the clinical significance of Helicobacter pylori infection has been validly determined within the development of a diversity of gastroduodenal diseases, including chronic gastritis, gastroduodenal ulcer, MALT lymphoma, and gastric adenocarcinoma. The Expert Council's Maastricht IV consensus (2010) determining international standards for the diagnosis and treatment of H. pylori infection is that there is evidence that the latter may be associated with the development of a number of extragastroduodenal diseases (EGDDs) presented by iron-deficiency anemia of unspecified etiology, idiopathic thrombocytopenic purpura, and vitamin B12 deficiency. Read More

    Cetirizine : A Reappraisal of its Pharmacological Properties and Therapeutic Use in Selected Allergic Disorders.
    Drugs 1993 Dec;46(6):1055-1080
    Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand.
    Synopsis: Cetirizine, the carboxylated metabolite of hydroxyzine, is a specific and long-acting histamine H1-receptor antagonist. It has marked antiallergic properties and inhibits eosinophil chemotaxis during the allergic response. Clinical trial results indicate that cetirizine is an effective and well tolerated treatment for seasonal/perennial allergic rhinitis and chronic idiopathic urticaria in adults, and for seasonal/perennial allergic rhinitis in children. Read More

    Review of Physical Urticarias and Testing Methods.
    Curr Allergy Asthma Rep 2017 Aug;17(8):51
    Allergy and Clinical Immunology Department, Centro Médico Docente La Trinidad, Caracas, Venezuela.
    Purpose Of Review: This review aims to update the information available on the prevalence, clinical picture, diagnostic methods, and treatment of urticarias induced by external physical stimuli.

    Recent Findings: Physical urticarias are present in up to 5% of the general population, and in 10 to 50% of patients with chronic urticaria. Recent investigations have provided evidence that the presence of physical urticaria alone or when comorbid with chronic spontaneous urticaria is associated with a worse prognosis and duration. Read More

    Functional and phenotypic analysis of basophils allows determining distinct subtypes in patients with chronic urticaria.
    Allergy 2017 Jun 5. Epub 2017 Jun 5.
    Clinical & Experimental Allergology, Department of Dermatology and Allergology, Philipps University Marburg, Marburg, Germany.
    Background: Chronic urticaria (CU) is a frequent skin disease characterized by relapsing appearance of pruritic hives. While clinical symptoms are due to the release of histamine by cutaneous mast cells, the underlying pathophysiology is still unknown. However, previous studies indicate that basophils might be of relevance. Read More

    Analysis of the changes in Th9 cells and related cytokines in the peripheral blood of spontaneous urticaria patients.
    Biomed Rep 2017 Jun 3;6(6):633-639. Epub 2017 May 3.
    Department of Dermatology, Peking Hepingli Hospital, Beijing 100013, P.R. China.
    Spontaneous urticaria (SU) is characterized by immune deregulation of mast cells and T helper (Th) cells. Th9 cells, a subset of Th cells, serve a key role in initiating mast cell accumulation and activation. To understand the role of Th9 cells in the pathogenesis of SU, the authors conducted a control study of 28 patients with acute SU (ASU) and chronic SU (CSU) and 28 healthy controls. Read More

    Increased serum soluble vascular endothelial cadherin levels in patients with chronic spontaneous urticaria.
    Ann Allergy Asthma Immunol 2017 Jun;118(6):704-709
    Department of Dermato-Venereology, Chengdu Second People's Hospital, Chengdu, Sichuan, China.
    Background: Chronic spontaneous urticaria (CSU) is a common skin disease characterized by recurrent itchy wheals with or without angioedema that lasts longer than 6 weeks. Vascular endothelial (VE)-cadherin is an endothelial cell-specific adhesion molecule that plays critical roles in angiogenesis and endothelial permeability.

    Objective: To investigate serum levels of soluble VE (sVE)-cadherin in patients with CSU. Read More

    Differential expression of microRNAs and their possible roles in patients with chronic idiopathic urticaria and active hives.
    Allergy Rhinol (Providence) 2017 Jun;8(2):67-80
    Background: Chronic idiopathic urticaria (CIU) is a complicated skin disease with unknown pathophysiology. MicroRNAs (miRNA) have been shown to be active in cellular regulation. The goal of this pilot study was to examine whether miRNAs may be involved in the regulation of CIU or as biomarkers for CIU. Read More

    The use of skin biomarker profiles to distinguish Schnitzler's syndrome from chronic spontaneous urticaria: results of a pilot study.
    Br J Dermatol 2017 Jun 5. Epub 2017 Jun 5.
    Dept. of Dermatology and Allergy, Allergie-Centrum-Charité, Charité - Universitätsmedizin Berlin, Germany.
    urticarial rash is a hallmark symptom of systemic autoinflammatory diseases such as Schnitzler's syndrome (SchS). Clinically, the urticarial rash cannot be distinguished from wheals in chronic spontaneous urticaria (CSU). Thus, it is commonly misdiagnosed as CSU. Read More

    Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria.
    J Eur Acad Dermatol Venereol 2017 Jun 2. Epub 2017 Jun 2.
    Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
    Background: Chronic spontaneous/idiopathic urticaria (CSU/CIU) has substantial detrimental effects on health-related quality of life (HRQoL) with an effect comparable to or worse than many other skin diseases.

    Objective: To assess the effect of omalizumab on CSU patients' HRQoL, measured by the Dermatology Life Quality Index (DLQI) in three phase III studies ASTERIA I, ASTERIA II, and GLACIAL.

    Methods: A post-hoc analysis examined changes in DLQI scores, distribution of patients across DLQI bands and the proportion reaching minimal clinically important difference (MCID) following omalizumab vs placebo. Read More

    Patient-reported outcomes (PROs) in chronic urticaria.
    Int J Dermatol 2017 Jun 1. Epub 2017 Jun 1.
    Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.
    Chronic urticaria is an itching skin disease which persists for more than 6 weeks. Chronic urticaria has great impact on the daily life of the patient, and the fluctuating nature of the symptoms complicates the monitoring and treatment of the disease. Currently, there are no reliable biomarkers to identify and measure disease activity in chronic spontaneous urticaria. Read More

    Treatment and retreatment with omalizumab in chronic spontaneous urticaria: Real life experience with twenty-five patients.
    Allergol Int 2017 May 26. Epub 2017 May 26.
    Division of Allergy and Clinical Immunology, Department of Chest Diseases, Erciyes University School of Medicine, Kayseri, Turkey.
    Background: Previous data have shown the high efficacy of omalizumab in chronic spontaneous urticaria (CSU). However, factors that may be effective on the response to therapy, relapse rates after drug discontinuation, and efficacy of retreatment remain unclear. This study aimed to determine the efficacy of omalizumab in CSU refractory to conventional therapy, to identify possible factors affecting treatment response and relapse, and also to evaluate the efficacy of retreatment on relapsed disease. Read More

    Knowledge and management of chronic spontaneous urticaria in Latin America: a cross-sectional study in Ecuador.
    World Allergy Organ J 2017 23;10(1):21. Epub 2017 May 23.
    Respiralab Research Group, Respiralab, Guayaquil, Ecuador.
    Background: The current EAACI/GA(2)LEN/EDF/WAO guideline for urticaria provide specific recommendations for the diagnostic workup and treatment of patients with chronic spontaneous urticaria (CsU). This study explored if physicians in Ecuador know these recommendations and implement them in their actual clinical practice for CsU.

    Methods: We investigated physicians who treat CsU patients in a cross-sectional study using a standardized questionnaire. Read More

    Why a registry of Chronic Urticaria (CUR) is needed.
    World Allergy Organ J 2017 16;10(1):16. Epub 2017 May 16.
    Fundación Ayre at Instituto Médico Alas, Sarmiento 771, 330-31, 4400 Salta, Argentina.
    Chronic urticaria (CU) has a major effect on patients' quality of life. While there have been progressive advances regarding its pathogenesis and treatment, much remains to be done. Registries of other chronic non-communicable diseases have shown many benefits, such as additional basic knowledge and management approaches to diabetes mellitus. Read More

    The Burden of Chronic Spontaneous Urticaria Is Substantial: Real-World Evidence From ASSURE-CSU.
    Allergy 2017 May 19. Epub 2017 May 19.
    Novartis Pharma AG, Basel, Switzerland.
    Background: Chronic spontaneous urticaria (CSU) can be debilitating, difficult to treat, and frustrating for patients and physicians. Real-world evidence for the burden of CSU is limited. The objective of this study was to document disease duration, treatment history, and disease activity, as well as impact on health-related quality of life (HRQoL) and work among patients with inadequately controlled CSU, and to describe its humanistic, societal, and economic burden. Read More

    Alternative treatments for chronic spontaneous urticaria beyond the guideline algorithm.
    Curr Opin Allergy Clin Immunol 2017 May 22. Epub 2017 May 22.
    aDermatology and Venereology Private Practice, Bari and Barletta, Italy bDepartment of Dermatology and Allergy, Allergie-Centrum-Charité, Charité-Universitätsmedizin Berlin, Berlin, Germany.
    Purpose Of Review: The international EAACI/GALEN/EDF/WAO guideline suggests a stepwise approach for the therapeutic management of chronic spontaneous urticaria (CSU), outlined in an algorithm. The aim of this article is to summarize and review the evidence available on alternative treatment options for CSU outside of this algorithm.

    Recent Findings: Although CSU is a common disease, there are a limited number of high-quality studies, and only antihistamines and omalizumab are licensed for its treatment. Read More

    [Skin diseases associated with environmental factors].
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2017 Jun;60(6):605-617
    Abteilung Allergologie, Paul-Ehrlich-Institut, Paul-Ehrlich-Str. 51-59, 63225, Langen, Deutschland.
    Background: Multiple environmental exposures may derange the regulatory and repair mechanisms of the skin and lead to dermatological disease.

    Objectives: Provide an overview of non-allergic skin diseases associated with environmental factors.

    Materials And Methods: Review of current scientific evidence for associations of non-allergic skin diseases with environmental exposures: irritation, chemicals, infection, UV-radiation, temperature. Read More

    Use of nonbiologic treatments in antihistamine-refractory chronic urticaria: a review of published evidence.
    J Dermatolog Treat 2017 May 31:1-18. Epub 2017 May 31.
    a Department of Dermatology , Bispebjerg Hospital , Copenhagen , Denmark.
    Background: Knowledge of effectiveness and safety of the nonbiologic, nonantihistamine treatments used for chronic urticaria is important as in some cases the principal guideline-recommended drug; omalizumab, has limited effect, side effects or is too expensive or unavailable. Herein, we systematically review the evidence for the use of the nonbiologic treatments in antihistamine-refractory chronic urticaria.

    Methods: We performed a systematic review of the literature using PubMed and Webofscience and identified studies that reported use of one or more of the nonbiological, nonantihistamine treatment options for chronic urticaria. Read More

    Antidepressants have Anti-inflammatory Effects that may be Relevant to Dermatology: A Systematic Review.
    Acta Derm Venereol 2017 May 17. Epub 2017 May 17.
    Department of Psychiatry, Oslo University Hospital, NO-0196 Oslo, Norway.
    There is increasing evidence of clinically relevant anti-inflammatory effects of monoaminergic antidepressants. PubMed and Ovid databases were searched systematically for the use and efficacy of antidepressants in association with 5 common inflammatory skin disorders: chronic urticaria, psoriasis, atopic dermatitis, other eczema, and alopecia areata. From January 1984 to June 2016, publications included a total of 1,252 dermatological patients in 28 trials or case reports. Read More

    Posttraumatic stress disorder (PTSD) and the dermatology patient.
    Clin Dermatol 2017 May - Jun;35(3):260-266. Epub 2017 Jan 22.
    Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
    Dermatologic symptoms can be associated with posttraumatic stress disorder (PTSD) in several situations: (1) as features of some core PTSD symptoms, such as intrusion symptoms manifesting as cutaneous sensory flashbacks, as autonomic arousal manifesting as night sweats and idiopathic urticaria, and as dissociation manifesting as numbness and dermatitis artefacta; (2) the cutaneous psychosomatic effects of emotional and physical neglect and sexual abuse (eg, infantile eczema, cutaneous self-injury, and body-focused repetitive behaviors such as trichotillomania and skin picking disorder) and eating disorders, which can have dermatologic effects; (3) the direct effect of physical or sexual abuse or catastrophic life events (eg, earthquakes) on the skin; and (4) as a result of significant alterations in hypothalamic-pituitary-adrenal and sympatho-adrenal medullary axes, which can affect neuroendocrine and immune functions, and can lead to exacerbations of stress-reactive inflammatory dermatoses such as psoriasis, chronic urticaria, and atopic dermatitis. Elevated levels of inflammatory biomarkers and impaired epidermal barrier function have been reported in situations involving sustained psychologic stress and sleep deprivation. Some PTSD patients show hypothalamic-pituitary-adrenal axis hyporesponsiveness and higher circulating T lymphocytes, which can exacerbate immune-mediated dermatologic disorders. Read More

    Comparative Efficacy and Safety of Ebastine 20 mg, Ebastine 10 mg and Levocetirizine 5 mg in Acute Urticaria.
    J Clin Diagn Res 2017 Mar 1;11(3):WC06-WC09. Epub 2017 Mar 1.
    Senior Resident, Department of Dermatology, Adesh Institute of Medical Sciences and Research, Bathinda, Punjab, India.
    Introduction: Acute and chronic urticaria can result in severely impaired quality of life from pruritus and associated sleep lessness, as well as anxiety and depression. Various treatment modalities are available out of which second generation non sedating H1 antihistamines e.g. Read More

    Sense of coherence as a protective factor in chronic urticaria.
    Postepy Dermatol Alergol 2017 Apr 13;34(2):168-173. Epub 2017 Apr 13.
    Psychodermatology Department, Medical University of Lodz, Lodz, Poland.
    Introduction: Chronic urticaria (CU) seems to be perceived as a psychodermatological disorder. Different psychological factors play an important role in CU triggering and course. One of them is a sense of coherence (SOC), which is believed to be a protective factor against anxiety and depression. Read More

    Increased Risk of Chronic Spontaneous Urticaria in Patients With Autoimmune Thyroid Diseases: A Nationwide, Population-based Study.
    Allergy Asthma Immunol Res 2017 Jul;9(4):373-377
    Department of Dermatology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
    There was no previous population-based study on the comparison of the risk of chronic spontaneous urticaria (CSU) between autoimmune thyroid diseases (AITD) and age- and gender-matched controls. The primary objective of this study was to evaluate the risk of CSU after diagnosis of AITD using national registry data from Korea. The secondary objective was to evaluate other risk factors of CSU. Read More

    The relationship between circulating concentrations of interleukin 17 and C reactive protein in chronic spontaneous urticaria.
    Allergy Asthma Clin Immunol 2017 10;13:25. Epub 2017 May 10.
    Department of Internal Diseases, Dermatology and Allergology, School of Medicine with Division of Dentistry in Zabrze, Medical University of Silesia in Katowice, Katowice, Poland.
    Background: Up-regulation of interleukin 17 (IL-17) family cytokines and acute phase response have been observed in patients with chronic spontaneous urticaria (CSU). It has been demonstrated that IL-17 stimulates C-reactive protein (CRP) expression.

    Aim: To determine relationship between circulating concentrations of IL-17 and CRP in CSU. Read More

    Tolerability and benefit of a tetramethoxyluteolin-containing skin lotion.
    Int J Immunopathol Pharmacol 2017 Jun 8;30(2):146-151. Epub 2017 May 8.
    1 Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Integrative Physiology and Pathobiology, Tufts University School of Medicine, Boston, MA, USA.
    As many as 40% of people have sensitive skin and at least half of them suffer from pruritus associated with allergies, atopic dermatitis (AD), chronic urticaria (CU), cutaneous mastocytosis (CM), and psoriasis. Unfortunately, the available topical formulations contain antihistamines that are often not as effective as those containing corticosteroids. Certain natural flavonoids have anti-inflammatory actions. Read More

    IgE sensitization to Anisakis pegreffii in Italy: Comparison of two methods for the diagnosis of allergic anisakiasis.
    Parasite Immunol 2017 Jul;39(7)
    Department of Translational Research, N.T.M.S., Pisa University, Pisa, Italy.
    IgE sensitization to Anisakis pegreffii in Italian subjects suffering from gastro-allergic anisakiasis (GAA) (N=5), or showing chronic urticaria (CU+) after fish consumption (N=100), was investigated. A control group (N=5) was also included. IgE response was analysed by immunoblotting (WB) assay, using both excretory/secretory products (ESPs) and crude extract (CE) of A. Read More

    [Chronic urticaria in childhood : Rational diagnostics and treatment].
    Hautarzt 2017 May 4. Epub 2017 May 4.
    Fachbereich Pädiatrische Dermatologie und Allergologie, Kinder- und Jugendkrankenhaus AUF DER BULT, Janusz-Korczak-Allee 12, 30173, Hannover, Deutschland.
    Chronic urticaria (CU) is defined by episodes of urticaria with or without angioedema, which recur daily or nearly daily over more than 6 weeks. Sudden manifestations of CU with or without known causes are termed chronic spontaneous urticaria, which is differentiated from chronic inducible urticaria. The differential diagnoses of CU in childhood range from self-limiting dermatoses to severe systemic diseases. Read More

    Adaptation and Validation of the Israeli Version of the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL).
    Isr Med Assoc J 2016 Aug;18(8):461-465
    Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, affiliated with Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
    Background: Chronic urticaria (CU) is a common disabling disorder. The CU-Q2oL (Chronic Urticaria Quality of Life Questionnaire) is a specific questionnaire for evaluating quality of life in CU patients. It consists of 23 items divided into six quality-of-life dimensions. Read More

    Increased cis-to-trans urocanic acid ratio in the skin of chronic spontaneous urticaria patients.
    Sci Rep 2017 May 2;7(1):1318. Epub 2017 May 2.
    Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Republic of Korea.
    Increased filaggrin expression was found to be correlated with severity scores in chronic spontaneous urticaria (CSU); however, the role of filaggrin breakdown products (FBPs) in CSU has not been studied. We collected stratum corneum (SC) specimens from the volar forearms of 10 CSU patients, 10 AD patients, and 10 healthy normal controls (NCs) and measured contents of FBPs (pyrrolidone carboxylic acid [PCA] and urocanic acid [UCA]) using UPLC-MS/MS, transepidermal water loss (TEWL) and epidermal pH. Compared to NCs, cis-UCA level was increased in CSU lesions (P < 0. Read More

    Improvement in the quality of life of patients with chronic spontaneous urticaria treated with omalizumab in real life.
    Enferm Clin 2017 Apr 27. Epub 2017 Apr 27.
    Servicio de Alergología, Ambulatorio Conde Oliveto, Servicio Navarro de Salud (Osasunbidea), Pamplona, España.
    Objective: Evaluation of the impact on the quality of life (QOL) relating to health in patients with chronic urticaria (CSU) treated with omalizumab.

    Method: Longitudinal descriptive observational study of quality of life based on18 patients with chronic urticaria ≥12 years treated with omalizumab. Changes in QOL examined at 1 month (T1), at 6 months (T6) and 12 months (T12), by: Visual Analogical Scale (UAS), specific urticaria QOL questionnaire (CU-Q2oL), general health questionnaire (SF-36) and activity of urticaria questionnaire (Score UAS7). Read More

    Response to Omalizumab in Solar Urticaria: Report of 3 Cases.
    Actas Dermosifiliogr 2017 Apr 27. Epub 2017 Apr 27.
    Servicio de Dermatología, Hospital Universitario de La Princesa, Madrid, España.
    We report 3 cases of solar urticaria in which there was no response or limited response to first-line treatments with high-dose H1 antihistamines or phototherapy. The patients were then treated with omalizumab. Symptoms improved in 2 patients, whose tolerance to sunlight increased considerably; quality of life clearly improved for 1 of these patients. Read More

    How to manage chronic urticaria 'beyond' guidelines: a practical algorithm.
    Clin Exp Allergy 2017 Jun;47(6):710-718
    Urticaria Clinic, St John's Institute of Dermatology, London, UK.
    Chronic urticaria (CU) is a disease characterized by pruritic weals, angio-oedema or both occurring for at least 6 weeks. It encompasses spontaneous and inducible urticarias. The national and international guidelines outline the principles of treatment. Read More

    A 30-year-old woman with chronic hives, intermittent fevers, and joint pain.
    Allergy Asthma Proc 2017 May;38(3):231-235
    Chronic urticaria with concomitant systemic symptoms may be seen in several rheumatologic and autoinflammatory conditions. Although most of these conditions tend to improve with corticosteroids, symptoms often recur with dose tapering. The appearance of the rash in addition to the symptom pattern and laboratory data must be considered to differentiate potential causes. Read More

    Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
    Theranostics 2017 6;7(5):1266-1276. Epub 2017 Mar 6.
    Department of Dermatology and Allergy, Charité - Universitätsmedizin, Berlin, Germany.
    Background. Treatment with omalizumab, a humanized recombinant monoclonal anti-IgE antibody, results in clinical efficacy in patients with Chronic Spontaneous Urticaria (CSU). The mechanism of action of omalizumab in CSU has not been elucidated in detail. Read More

    New Perspectives on the Diagnosis of Allergy to Anisakis spp.
    Curr Allergy Asthma Rep 2017 May;17(5):27
    Unit of Immunology, University Hospital La Paz, Paseo de La Castellana 261, 28046, Madrid, Spain.
    Purpose Of Review: To compare the prevalence of sensitization in different countries based on specific IgE values and to evaluate the use of isolated native or recombinant allergens for diagnosis.

    Recent Findings: Isolated allergens help in the diagnosis of truly sensitized patients avoiding false positives due to cross-reactions. Their use is therefore highly recommended, especially when used as a combination of several relevant allergens. Read More

    Thyroid Autoimmunity in Patients with Chronic Urticaria.
    Med Arch 2017 Feb 5;71(1):29-31. Epub 2017 Feb 5.
    Department of Dermatology and Venereology, University Clinical Center Sarajevo, Bosnia and Herzegovina.
    Introduction: chronic urticaria (CU) is a skin disorder characterized by transient, pruritic wheals persisting for longer than 6 weeks. The etiopathogenesis of the disease is still unclear, but there is evidence that autoimmunity and endocrine dysfunction may be involved.

    Aim: the aim of this study was to determine whether chronic urticaria is statistically associated with thyroid autoimmunity. Read More

    Transcriptome analysis of severely active chronic spontaneous urticaria shows an overall immunological skin involvement.
    Allergy 2017 Apr 13. Epub 2017 Apr 13.
    Department of Dermatology, Hospital del Mar IMIM, Universitat Autònoma de Barcelona, Barcelona, Spain.
    Background: The knowledge about chronic spontaneous urticaria (CSU) phenotypes is based on its clinical characteristics, associated comorbidities, course of the disease, and its response to the available effective drugs. Genotype expression and its further correlation with CSU phenotypes are still unknown. We describe the cutaneous transcriptome of patients suffering a severely active CSU refractory to antihistamine treatment. Read More

    Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: A systematic review.
    Allergy 2017 Apr 13. Epub 2017 Apr 13.
    Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
    Patients with chronic spontaneous urticaria (CSU) are widely held to often have other autoimmune disorders, including autoimmune thyroid disease. Here, we systematically evaluated the literature on the prevalence of thyroid autoimmunity in CSU and vice versa. There is a strong link between CSU and elevated levels of IgG antithyroid autoantibodies (AAbs), with most of a large number of studies reporting rates of ≥10%. Read More

    Autologous Serum and Plasma Skin Tests in Chronic Spontaneous Urticaria: A Reappraisal.
    Indian Dermatol Online J 2017 Mar-Apr;8(2):94-99
    Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
    Aim: The objective of this study was to assess autologous serum skin test (ASST) vs autologous plasma skin test (APST) response in chronic spontaneous urticaria (CSU) patients and study the significance of intensity of positive responses in relation to clinicoepidemiological parameters.

    Materials And Methods: One hundred CSU patients and 100 age and sex-matched controls were recruited. The demographic and clinical features were recorded in all patients and routine investigations were performed. Read More

    Imatinib mesylate-induced lichenoid drug eruption.
    Cutis 2017 Mar;99(3):189-192
    Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, USA.
    Imatinib mesylate (imatinib) is a tyrosine kinase inhibitor initially approved by the US Food and Drug Administration in 2001 for chronic myeloid leukemia (CML). Since then, the number of indicated uses for imatinib has substantially increased. It is increasingly important that dermatologists recognize adverse cutaneous manifestations of imatinib and are aware of their management and outcomes to avoid unnecessarily discontinuing a potentially lifesaving medication. Read More

    Clinical features of adolescents with chronic idiopathic or spontaneous urticaria: Review of omalizumab clinical trials.
    Ann Allergy Asthma Immunol 2017 Apr;118(4):500-504
    Department of Medicine, Allegheny General Hospital, Pittsburgh, Pennsylvania.
    Background: Adults and adolescents were included in 3 phase 3 omalizumab trials in chronic idiopathic urticaria (CIU): ASTERIA I, ASTERIA II, and GLACIAL.

    Objective: To describe the baseline clinical profile of adolescent patients with CIU enrolled in the omalizumab trials to add to the limited literature available on CIU in this population.

    Methods: Data for patient demographics, baseline clinical disease characteristics, medical history, and previous CIU medication information (not efficacy assessments) from phase 3 omalizumab trials were pooled and descriptive statistical analyses performed for adolescent (12 to <18 years old) and adult (≥18 years old) subgroups. Read More

    Effectiveness of Autologous Whole-Blood Injections in Patients with Refractory Chronic Spontaneous Urticaria.
    Int Arch Allergy Immunol 2017 6;172(3):161-166. Epub 2017 Apr 6.
    Allergy Department, 2nd Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.
    Background: Nonsedating antihistamines are the treatment of choice for chronic spontaneous urticaria (CSU), while omalizumab and immunosuppressants have also been approved as an add-on treatment. Autologous whole-blood injection (AWBI) has been used in previous studies with ambiguous results. The aim of our study was to evaluate changes in the Urticaria Activity Score (UAS7), Dermatology Life Quality Index (DLQI), and Chronic Urticaria Quality of Life (CU-Q2oL) score, and also the association of serologic markers with disease severity measures after AWBI. Read More

    The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field.
    Eur J Clin Pharmacol 2017 Jul 4;73(7):799-809. Epub 2017 Apr 4.
    IBS Granada, University of Granada, CIBER of Epidemiology and Public Health (CIBERESP), Granada, Spain.
    Background: Cysteinyl leukotrienes (LTC4, LTD4, and LTE4) are pro-inflammatory mediators of the 5-lipooxygenase (5-LO) pathway, that play an important role in bronchoconstriction, but can also enhance endothelial cell permeability and myocardial contractility, and are involved in many other inflammatory conditions. In the late 1990s, leukotriene receptor antagonists (LTRAs) were introduced in therapy for asthma and later on, approved for the relief of the symptoms of allergic rhinitis, chronic obstructive pulmonary disease, and urticaria. In addition, it has been shown that LTRAs may have a potential role in preventing atherosclerosis progression. Read More

    Low-dose rituximab as an adjuvant therapy in pemphigus.
    Indian J Dermatol Venereol Leprol 2017 May-Jun;83(3):317-325
    Department of Dermatology, NHL Medical College, VS Hospital, Ahmedabad, Gujarat, India.
    Background: Pemphigus is a chronic autoimmune blistering disease where systemic steroids and immunosuppressants are the mainstay of therapy, but long-term treatment with these agents is associated with many side effects. Rituximab, a chimeric monoclonal anti-CD20 antibody, in low doses has shown efficacy as an adjuvant to reduce the dose of steroids.

    Aim: To study the clinical efficacy and safety of low-dose rituximab as an adjuvant therapy in pemphigus. Read More

    Biologic Therapy in the Treatment of Chronic Skin Disorders.
    Immunol Allergy Clin North Am 2017 May 1;37(2):315-327. Epub 2017 Mar 1.
    Department of Allergy and Clinical Immunology, Respiratory Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA. Electronic address:
    Understanding of the immunologic pathways involved in the pathogenesis of skin-related diseases is constantly advancing. Several biologic agents play important therapeutic roles for management of patients with chronic urticaria, atopic dermatitis, and psoriasis, particularly omalizumab for antihistamine-resistant chronic urticaria, interleukin (IL)-1 inhibitors for cryopyrin-associated periodic syndrome and Schnitzler syndrome, dupilumab for recalcitrant atopic dermatitis, and IL-17 inhibitors for psoriasis. The therapeutic utility of biologic agents for patients with immune-related dermatologic disorders is likely to expand in the future. Read More

    1 OF 86